Bipolar Disorder Clinical Trials in Houston

View 15 new treatments for Bipolar Disorder in Houston, TX, and other areas near me, such as League City, Pearland and Sugar Land. Every day, Power helps hundreds of bipolar patients connect with leading medical research.
View 14 trials in Houston
Filter (14)

Multiple Medications for Bipolar Depression

Research Clinic, Houston + 1 more

This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Bipolar Disorder in Youth

AbbVie Clinic, Houston + 6 more

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director

NRX-101 for Bipolar Depression

NeuroRx Clinic, Houston + 1 more

This trial tests a two-step treatment for adults with severe bipolar depression and suicidal thoughts. It starts with a quick-acting ketamine dose followed by an oral medication to maintain improvement. The goal is to see if this approach is better than using lurasidone alone. Ketamine has been shown to rapidly reduce depressive and suicidal symptoms in both unipolar and bipolar depression.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Martin Brecher, MD
Study Director

Lumateperone for Pediatric Bipolar Depression

Intra-Cellular Therapies Clinic, Houston + 1 more

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Pediatric Schizophrenia

AbbVie Clinic, Bellaire + 4 more

This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
ALLERGAN INC.
Study Director

ALTO-100 for Bipolar Depression

Alto Neuroscience Clinic, Houston + 1 more

The purpose of this study is to assess antidepressant efficacy differences between ALTO-100 and placebo during the Double-Blind period in patients with bipolar disorder I or II with current major depressive episode, when used adjunctively to a mood stabilizer, related to patient characteristics. Additionally, safety, tolerability, and efficacy will be assessed in a subsequent open label treatment period.Show More
Recruiting
Phase 2
Est. 5 - 8 Weeks
Mallory Loflin, PhD
Study Director

Psilocybin for Bipolar Disorder

Research Clinic, Houston + 1 more

The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.Show More
Waitlist

No Placebo Trial

Phase 2
Est. 6 - 12 Weeks
Thomas Meyer, PhD
Principal Investigator

ABBV-932 for Bipolar Disorder

AbbVie Clinic, Richmond + 1 more

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting
Phase 2
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director

Palmitoylethanolamide for Bipolar Depression

Research Clinic, Houston + 1 more

The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levelsShow More
Recruiting
Phase 2
Est. 5 - 8 Weeks
Rodrigo Machado-Vieira, M.D, Ph.D., M.Sc
Principal Investigator

Stem Cell Therapy for Bipolar Depression

Research Clinic, Houston + 1 more

This trial uses special cells from donated bone marrow to treat patients with bipolar depression who haven't responded to standard treatments. The cells may help by reducing inflammation and promoting brain healing. This approach has shown promise in preventing depression and anxiety in animal studies.Show More
Recruiting
Phase 1
Est. 3 - 6 Weeks
Jair C Soares, MD, PhD
Principal Investigator
Page 1 of 2

Frequently Asked Questions

How much do bipolar clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do bipolar clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across bipolar trials in Houston, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for bipolar patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Houston is research being conducted for bipolar?

The University of Texas Health Science Center at Houston is conducting clinical trials for bipolar disorder, with approximately 5 trials ongoing as of 2024. These trials are located in the central area of Houston.

What promising new drugs are being tested?

In Houston, research for bipolar disorder includes treatments like Atypical Antipsychotics and various Procedures. Specific interventions being studied are Cariprazine, Deep Brain Stimulation, and the VNS Therapy® System.